NASDAQ:EXEL - Exelixis Stock Price, Forecast & News

Exelixis trades on the NASDAQ under the ticker symbol "EXEL."

Exelixis, Inc. (NASDAQ:EXEL) issued its quarterly earnings results on Wednesday, October, 30th. The biotechnology company reported $0.31 EPS for the quarter, topping the consensus estimate of $0.19 by $0.12. The biotechnology company earned $271.70 million during the quarter, compared to analyst estimates of $228.17 million. Exelixis had a net margin of 64.05% and a return on equity of 25.55%. Exelixis's revenue for the quarter was up 20.5% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.44 earnings per share. View Exelixis' Earnings History.

Exelixis is scheduled to release their next quarterly earnings announcement on Tuesday, February 25th 2020. View Earnings Estimates for Exelixis.

Exelixis will be holding an earnings conference call on Wednesday, February 26th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

12 Wall Street analysts have issued 1-year price objectives for Exelixis' stock. Their forecasts range from $19.00 to $35.00. On average, they expect Exelixis' stock price to reach $26.70 in the next year. This suggests a possible upside of 26.6% from the stock's current price. View Analyst Price Targets for Exelixis.

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Exelixis in the last year. There are currently 3 hold ratings and 9 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Exelixis.

Media coverage about EXEL stock has been trending very negative on Monday, InfoTrie Sentiment reports. The research group ranks the sentiment of media coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Exelixis earned a media sentiment score of -3.0 on InfoTrie's scale. They also assigned press coverage about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the company's share price in the near term. View News Stories for Exelixis.

Exelixis saw a increase in short interest in the month of January. As of January 15th, there was short interest totalling 18,100,000 shares, an increase of 17.0% from the December 31st total of 15,470,000 shares. Based on an average trading volume of 2,940,000 shares, the short-interest ratio is currently 6.2 days. Currently, 6.2% of the company's stock are sold short. View Exelixis' Current Options Chain.

Some companies that are related to Exelixis include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Regeneron Pharmaceuticals (REGN), Alexion Pharmaceuticals (ALXN), Seattle Genetics (SGEN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS) and Repligen (RGEN).

Based on aggregate information from My MarketBeat watchlists, some companies that other Exelixis investors own include Micron Technology (MU), NVIDIA (NVDA), Advanced Micro Devices (AMD), Alibaba Group (BABA), Gilead Sciences (GILD), Incyte (INCY), Intel (INTC), BioMarin Pharmaceutical (BMRN), Corbus Pharmaceuticals (CRBP) and Puma Biotechnology (PBYI).

Exelixis' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Renaissance Technologies LLC (5.91%), State Street Corp (3.64%), FMR LLC (3.21%), AJO LP (2.51%), AQR Capital Management LLC (2.50%) and Farallon Capital Management LLC (2.47%). Company insiders that own Exelixis stock include Alan M Garber, Carl B Feldbaum, Charles Cohen, Christopher J Senner, George A Scangos, George Poste, Gisela Schwab, Jeffrey Hessekiel, Lance Willsey, Michael Morrissey, Patrick J Haley, Peter Lamb, Stelios Papadopoulos and Vincent T Marchesi. View Institutional Ownership Trends for Exelixis.

EXEL stock was sold by a variety of institutional investors in the last quarter, including AQR Capital Management LLC, FMR LLC, Goldman Sachs Group Inc., Pictet Asset Management Ltd., Great West Life Assurance Co. Can, Fiera Capital Corp, UBS Group AG and Prudential Financial Inc.. Company insiders that have sold Exelixis company stock in the last year include Alan M Garber, Charles Cohen, Christopher J Senner, George A Scangos, George Poste, Gisela Schwab, Jeffrey Hessekiel, Lance Willsey, Michael Morrissey, Patrick J Haley, Peter Lamb and Vincent T Marchesi. View Insider Buying and Selling for Exelixis.

EXEL stock was bought by a variety of institutional investors in the last quarter, including Farallon Capital Management LLC, AJO LP, Bank of Montreal Can, Renaissance Technologies LLC, State Street Corp, First Trust Advisors LP, Acadian Asset Management LLC and Man Group plc. View Insider Buying and Selling for Exelixis.

Shares of EXEL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of EXEL stock can currently be purchased for approximately $21.09.

Exelixis has a market capitalization of $6.41 billion and generates $853.83 million in revenue each year. The biotechnology company earns $690.07 million in net income (profit) each year or $1.43 on an earnings per share basis. Exelixis employs 484 workers across the globe.View Additional Information About Exelixis.

The official website for Exelixis is http://www.exelixis.com/.

Exelixis' mailing address is 1851 Harbor Bay Parkway, Alameda CA, 94502. The biotechnology company can be reached via phone at 650-837-7000 or via email at [email protected]